Our findings reveal CB2Rs as potential new targets of investigation for possible therapeutic development in neuropsychiatric and neurological disorders as the human genome wide association studies (GWAS) secondary analysis indicate that the CNR2 gene is associated with Parkinson’s disease and substance use disorders. This evidence concerns the gene CNR2 and Parkinson disease.